| Valuation method | Value, € | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | n/a | n/a |
| Intrinsic value (DCF) | n/a | |
| Graham-Dodd Method | 0.01 | -92 |
| Graham Formula | 0.01 | -94 |
Visiomed Group SA is a Paris-based medical technology company specializing in the development and distribution of electronic medical devices across Europe and internationally. The company offers a diverse portfolio of products, including thermometers, blood pressure monitors, pulse oximeters, connected blood glucometers, electrocardiograms, pain relief electrotherapy devices, connected scales, baby scales, humidifiers, phototherapies, hearing aids, and family hygiene products. Its well-known brands include ThermoFlash, T. LeClerc, Visiocheck, Innoxa, and BewellConnect. Founded in 2007, Visiomed Group operates in the Medical Instruments & Supplies sector, catering to both consumer and professional healthcare markets. The company focuses on connected health solutions, positioning itself at the intersection of medical devices and digital health innovation. With a market capitalization of approximately €53 million, Visiomed serves a growing demand for home healthcare and preventive medicine solutions in Europe's aging population.
Visiomed Group presents a niche investment opportunity in the European medical devices market, with particular exposure to connected health technologies. The company's €13.7 million revenue and €902,000 net income in FY2023 demonstrate modest but positive operations, supported by €1.1 million in operating cash flow. A negative beta of -0.625 suggests low correlation with broader markets, potentially offering portfolio diversification benefits. However, investors should note the company's small scale relative to industry leaders, €7.9 million in debt, and significant capital expenditures (-€2.6 million) that may pressure cash reserves (€2.9 million). The lack of dividend payments reflects reinvestment priorities. Growth prospects depend on adoption of connected health devices in Europe, where Visiomed's multi-brand strategy provides broad market coverage but may face increasing competition from larger medtech firms expanding into consumer health segments.
Visiomed Group competes in the fragmented consumer and professional medical devices market, differentiating through its portfolio of connected health products and multiple brand offerings. The company's competitive advantage lies in its specialized focus on diagnostic and monitoring devices for home use, particularly its connected offerings under the BewellConnect brand that address the growing telemedicine trend. However, as a smaller player (€53M market cap), Visiomed lacks the R&D scale of multinational medtech firms and depends on distribution partnerships. Its multi-brand strategy allows targeting different price points and channels but may create complexity. The French base provides home market strength but limits geographic diversification versus global competitors. Visiomed's product breadth across diagnostics, therapeutics, and hygiene is unusual for its size but risks spreading resources thin. The company shows financial viability (positive net income) but will need to demonstrate it can scale profitably against larger competitors increasingly targeting the connected home health space. Success may depend on forging strategic partnerships or focusing on underserved niches within its broad product range.